MedTrace Logo

Adalimumab in Adult Japanese Subjects With Psoriasis

NCT00647400 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2011-04-08

Study results available
· View outcomes & findings →

Summary

To evaluate efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with psoriasis

Conditions

Interventions

BIOLOGICAL

adalimumab

Adalimumab 40 mg every other week, subcutaneous

BIOLOGICAL

adalimumab

Adalimumab 80 mg every other week, subcutaneous

Sponsors & Collaborators

  • Abbott Japan Co.,Ltd

    collaborator INDUSTRY

  • Eisai Co., Ltd.

    collaborator INDUSTRY

  • Abbott

    lead INDUSTRY

Principal Investigators

  • Kazuko Kobayashi · Abbott

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-09-30
Completion
2010-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00647400 on ClinicalTrials.gov